Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMHN Wayrilz (rilzabrutinib) Coverage Prior Auth | …
    Ask Trek AI about this page
    CurrentmhnPolicy CP.PHAR.751

    Rilzabrutinib (Wayrilz)

    Customize your policy alerts

    Sign up for mhn Policy CP.PHAR.751 alerts

    Get alerted when Policy CP.PHAR.751 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization criteria for Wayrilz (rilzabrutinib) for adult patients with persistent or chronic immune thrombocytopenia (ITP) across specified lines of business.

    Policy Summary
    Payermhn
    PolicyRilzabrutinib (Wayrilz) coverage for immune thrombocytopenia
    Policy CodePolicy CP.PHAR.751
    Change TypeNo material changes
    Effective DateDec 1, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization with clinical documentation demonstrating diagnosis of persistent or chronic ITP, hematologist involvement, age ≥18, platelet/bleeding criteria, and prior treatment failure or intolerance.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥18min age
    <30k/µLplatelet threshold
    800 mg/daymax daily dose
    12 monthsapproval period
    400 mg tabletproduct strength

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Centene-ownedpolicy owner

    Coverage Criteria for Wayrilz (rilzabrutinib)

    inv-01: Initial Therapy

    Covered when ALL of the following are met

    Initial Approval - ITP: 1. Diagnosis of persistent or chronic immune thrombocytopenia (ITP) (see Appendix D); 2. Prescribed by or in consultation with a hematologist; 3. Age ≥ 18 years; 4. One of the following: (a) current (within 30 days) platelet count < 30,000/µL; OR (b) member has an active bleed; 5. One of the following: (a) failure of a systemic corticosteroid; OR (b) intolerance or contraindication to systemic corticosteroids AND failure of an immune globulin unless contraindicated or clinically significant adverse effects are experienced; 6. Wayrilz (rilzabrutinib) is not prescribed concurrently with rituximab, a thrombopoietin receptor agonist (e.g., Doptelet, Promacta, Mulpleta, Nplate), or a spleen tyrosine kinase inhibitor (e.g., Tavalisse); 7. Dose does not exceed 800 mg (2 tablets) per day.see node text

    Approval duration: 12 months

    inv-02: Continuation Therapy

    Covered for continuation when ALL of the following are met

    Continuation Therapy - ITP: 1. Member meets one of the following: (a) currently receiving medication via Centene benefit or previously met initial approval criteria; OR (b) currently receiving medication and enrolled in a state/product with continuity of care regulations; 2. Member is responding positively to therapy (e.g., increase in platelet count from baseline, reduction in bleeding events); 3. Wayrilz is not prescribed concurrently with rituximab, a thrombopoietin receptor agonist (e.g., Doptelet, Promacta, Mulpleta, Nplate), or a spleen tyrosine kinase inhibitor (e.g., Tavalisse); 4. If request is for a dose increase, new dose does not exceed 800 mg (2 tablets) per day.see node text

    Approval duration: 12 months

    Non‑FDA approved indications that are not specifically addressed in this policy are not authorized unless the provider supplies sufficient documentation of efficacy and safety in accordance with the applicable off‑label use policies: CP.CPA.09 (Commercial), HIM.PA.154 (Health Insurance Marketplace), or CP.PMN.53 (Medicaid), or the member's evidence of coverage documents.

    Coverage decisions and the administration of benefits for rilzabrutinib are governed by the member's coverage documents and applicable Health Plan administrative policies. This clinical policy is a guide to medical necessity and does not constitute a contract or guarantee of payment; therefore, all determinations remain subject to the terms, conditions, exclusions and limitations of the applicable evidence of coverage, certificate of coverage, policy, contract of insurance, and to state and federal requirements.

    Requests for rilzabrutinib to treat non‑FDA approved indications that are not addressed in this policy require supporting documentation per the Health Plan’s off‑label use policies. Without sufficient evidence of efficacy and safety as defined in those referenced off‑label policies, such requests are not authorized.

    inv-06: Platelet count threshold
    Platelet count threshold for authorizationCurrent platelet count < 30,000/µL (measured within 30 days) is an initial-approval criterion
    Response definition (per 2019 ASH guidelines)Platelet count ≥ 30,000/µL and >2‑fold increase from baseline measured on 2 occasions >7 days apart and absence of bleeding
    Failure definition (per 2019 ASH guidelines)A failure is defined as platelet count < 30,000/µL or <2‑fold increase from baseline or presence of bleeding; platelets must be measured on 2 occasions >1 day apart

    Provider Requirements and Prior Authorization

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Submit documentation demonstrating diagnosis of persistent or chronic immune thrombocytopenia, specialist involvement (prescribed by or in consultation with a hematologist), age ≥ 18 years, and platelet/bleeding criteria (current platelet count < 30,000/µL within 30 days or active bleed). Prior authorization may also be required for immune globulin therapy where relevant.

    • Approval duration: 12 months
    • Dose limit: ≤ 800 mg (2 tablets) per day
    • Wayrilz must not be used concurrently with rituximab, thrombopoietin receptor agonists (e.g., Doptelet®, Promacta®, Mulpleta®, Nplate®), or spleen tyrosine kinase inhibitors (e.g., Tavalisse™)
    Documentation Required

    Required Clinical Documentation

    Providers must submit supporting clinical documentation such as office chart notes, relevant laboratory results (including recent platelet counts), and any consultation notes that substantiate meeting all approval criteria. Failure to provide required documentation or to supply requested reauthorization information may result in denial or delay of the request.

    Initial Authorization Criteria and Dosing

    inv-20: Initial Therapy

    Initial authorization criteria and dosing

    Initial: 1. Diagnosis of persistent or chronic ITP; 2. Prescribed by or in consultation with a hematologist; 3. Age ≥ 18 years; 4. Current platelet count < 30,000/µL (within 30 days) OR active bleed; 5. Prior failure of a systemic corticosteroid OR intolerance/contraindication to systemic corticosteroids AND failure of an immune globulin unless contraindicated or clinically significant adverse effects are experienced; 6. Not prescribed concurrently with rituximab, a thrombopoietin receptor agonist, or a spleen tyrosine kinase inhibitor; 7. Dosing: 400 mg PO twice daily (400 mg BID) with a maximum dose of 800 mg/day (2 tablets per day).Dose: 400 mg PO BID; Max 800 mg/day

    Approval duration: 12 months

    Continuation Authorization Criteria

    inv-21: Continuation Therapy

    Continuation criteria for ITP

    Continuation: 1. Member meets continuity criterion (currently receiving medication via benefit or previously met initial approval criteria OR enrolled in state/product with continuity of care); 2. Member demonstrates positive response to therapy (e.g., increase in platelet count from baseline, reduction in bleeding events); 3. Wayrilz is not prescribed concurrently with rituximab, a thrombopoietin receptor agonist, or a spleen tyrosine kinase inhibitor; 4. If dose increase is requested, new dose does not exceed 800 mg (2 tablets) per day.

    Prior Treatment Requirements / Step Therapy

    StepRequired prior treatment failure or intolerance
    1Failure of a systemic corticosteroid; if systemic corticosteroids are contraindicated or not tolerated, failure of an immune globulin unless contraindicated or clinically significant adverse effects are experienced

    Coding, Thresholds, and Related Values

    inv-06: Platelet count threshold
    Authorization platelet criterionCurrent (within 30 days) platelet count < 30,000/µL required for one pathway to initial approval
    Alternate initial criterionActive bleeding at time of assessment may substitute for platelet threshold
    Response metric used in continuationResponse defined as platelet count ≥ 30,000/µL with >2‑fold increase from baseline on 2 occasions >7 days apart and no bleeding

    Quantity Limits and Product Information

    inv-23: Wayrilz (rilzabrutinib) — quantity limit / maximum dose (800 mg)
    Maximum daily dose800 mg per day (maximum) — equivalent to 2 tablets/day
    Typical dosing regimen400 mg PO twice daily (400 mg tablet availability)
    Quantity limit recordQuantity limits specify 800 mg per day as the allowable maximum

    Site of Care Restrictions

    Note

    No site-of-care restrictions specified

    No site-of-care restrictions are specified in this section of the policy.

    Definitions and Clinical Terms

    inv-16: Immune thrombocytopenia (ITP) — newly diagnosed, persistent, chronic timeframes
    Newly diagnosed ITPNewly diagnosed: diagnosis to 3 months from onset (per International Working Group)
    Persistent ITPPersistent: 3 to 12 months from diagnosis
    Chronic ITPChronic: lasting for more than 12 months
    inv-17: Response to treatment (per 2019 ASH guidelines) — platelet count criteria for response
    Primary response criterionPlatelet count ≥ 30,000/µL and a >2‑fold increase from baseline measured on 2 occasions >7 days apart and absence of bleeding
    Measurement timingPlatelet measurements must be taken on two occasions more than 7 days apart for full response assessment

    Background and Drug Information

    Rilzabrutinib (Wayrilz) is an oral Bruton's tyrosine kinase (BTK) inhibitor available as a 400 mg tablet. It is FDA‑approved for the treatment of adult patients with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to prior treatment. The approved dosing for ITP is 400 mg PO twice daily (maximum 800 mg/day), and authorization is intended for adults aged ≥ 18 years. ITP classifications and response definitions referenced in this policy follow international consensus and ASH guidance (e.g., response often defined as platelet count ≥30,000/µL with a >2‑fold increase from baseline and absence of bleeding).

    Policy Summary
    Payermhn
    PolicyRilzabrutinib (Wayrilz) coverage for immune thrombocytopenia
    Policy CodePolicy CP.PHAR.751
    Change TypeNo material changes
    Effective DateDec 1, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization with clinical documentation demonstrating diagnosis of persistent or chronic ITP, hematologist involvement, age ≥18, platelet/bleeding criteria, and prior treatment failure or intolerance.
    SourceLink
    On This Page
    Coverage Criteria for Wayrilz (rilzabrutinib)Provider Requirements and Prior AuthorizationInitial Authorization Criteria and DosingContinuation Authorization CriteriaPrior Treatment Requirements / Step TherapyCoding, Thresholds, and Related ValuesQuantity Limits and Product InformationSite of Care RestrictionsDefinitions and Clinical TermsBackground and Drug Information
    • Examples: office notes, platelet lab results within 30 days, hematology consult notes, records of prior therapies and responses
    Documentation Required

    Documentation and Contractual Compliance

    Coverage decisions are governed by the member's benefit plan and applicable contracts. Authorization and payment remain subject to the terms, conditions, exclusions, and limitations of the member's evidence of coverage, certificate of coverage, policy, contract of insurance, and state/federal requirements. Providers should follow any additional Health Plan-level administrative policies and contractual obligations.

    • Authorizations do not guarantee payment — adjudication follows member benefit terms
    • State continuity-of-care requirements may affect coverage for members currently receiving therapy
    Step Therapy

    Therapeutic Alternatives / Prior Therapy Expectations

    Therapeutic alternatives and prior therapy expectations: members must have failed systemic corticosteroids or have intolerance/contraindication to them and have failed immune globulin therapy unless immune globulin is contraindicated or causes clinically significant adverse effects. Prior authorization may be required for immune globulins (see Appendix B). Review Appendix B and state-specific addenda for details on acceptable prior therapies and dosing.

    • Required prior therapy: systemic corticosteroid failure OR intolerance/contraindication plus immune globulin failure (unless contraindicated)
    • Prior‑authorization may be required for immune globulins — check plan-specific requirements (Appendix B)
    Denial Risk

    Grounds for Denial

    Denials may be issued if requested services fall outside the member's benefit terms (exclusions, limits, or lack of coverage), if required documentation is not supplied, if clinical criteria are not met, or if concurrent excluded therapies are prescribed. Providers and members may appeal adverse determinations per the member's plan procedures.

    • Common denial reasons: missing documentation, failure to meet medical necessity criteria, contract exclusions or limitations, concurrent use with excluded agents
    Failure per ASHFailure: platelet count < 30,000/µL or <2‑fold increase from baseline or presence of bleeding
    inv-18: Clinical policy — definition of clinical policy as a guide to medical necessity
    Role of clinical policyA clinical policy provides a guide to medical necessity to assist in making coverage decisions and administering benefits; it is not a contract or guarantee of payment
    Basis for developmentDeveloped by licensed health care professionals using current standards of medical practice and available clinical information
    LimitationsDoes not constitute medical advice or dictate provider practice; coverage is subject to terms, conditions, exclusions, and limitations of coverage documents
    inv-19: Health Plan — definition of Health Plan referenced in the policy
    Definition of Health PlanHealth Plan means a plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC or its affiliates
    Relation to policy adoptionThe Health Plan adopts the clinical policy effective as determined by the Health Plan; posting date may differ from effective date
    Coverage governanceCoverage decisions and benefit administration are subject to the Health Plan's coverage documents and applicable administrative policies and procedures